Cachexia in patients with cancer

被引：4

作者：

Jafri, Syed H. ^{[1
]}

机构：

[1] Univ Texas Houston, Houston, TX USA

来源：

LANCET ONCOLOGY | 2016年 / 17卷 / 06期

关键词：

CELL LUNG-CANCER;

D O I：

10.1016/S1470-2045(16)30057-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：E220 / E221

页数：3

共 5 条

[1] Validation of the Consensus-Definition for Cancer Cachexia and evaluation of a classification model-a study based on data from an international multicentre project (EPCRC-CSA) [J].

Blum, D. ;

Stene, G. B. ;

Solheim, T. S. ;

Fayers, P. ;

Hjermstad, M. J. ;

Baracos, V. E. ;

Fearon, K. ;

Strasser, F. ;

Kaasa, S. .

ANNALS OF ONCOLOGY, 2014, 25 (08) :1635-1642

[2]

Crawford JC, 2014, SUPPORT CARE CANC S1, V22, pS1

[3] Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review [J].

Jafri, Syed H. ;

Shi, Runhua ;

Mills, Glenn .

BMC CANCER, 2013, 13

[4] The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancer [J].

McMillan, Donald C. .

CANCER TREATMENT REVIEWS, 2013, 39 (05) :534-540

[5] Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials [J].

Temel, Jennifer S. ;

Abernethy, Amy P. ;

Currow, David C. ;

Friend, John ;

Duus, Elizabeth M. ;

Yan, Ying ;

Fearon, Kenneth C. .

LANCET ONCOLOGY, 2016, 17 (04) :519-531

← 1 →